A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma

NCT07392866 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG: SH006
DRUG: Bevacizumab
DRUG: Oxaliplatin injection
DRUG: Capecitabine
DRUG: Regorafenib

Sponsor

Nanjing Sanhome Pharmaceutical, Co., Ltd.